Cigna said adjusted revenues for Evernorth Health Services increased 15% for the 3 months and 16% for the 9 months, and pre-tax adjusted income from operations increased 1% and 4%, respectively. The company cited higher utilization of prescription drugs from customer growth and an increase due to claims composition as drivers of the revenue increase.

1. 01

   Cigna said adjusted revenues for Evernorth Health Services increased 15% for the 3 months and 16% for the 9 months, and pre-tax adjusted income from operations increased 1% and 4%, respectively. The company cited higher utilization of prescription drugs from customer growth and an increase due to claims composition as drivers of the revenue increase.

2. 02

   Cigna said adjusted revenues for Cigna Healthcare decreased 18% ($2,408 million) for the 3 months and 9% ($3,592 million) for the 9 months, with the HCSC transaction impact of -$2,998 million and -$5,524 million, respectively. The medical care ratio increased 200 basis points for the 3 months and 160 basis points for the 9 months.

3. 03

   Cigna said in September 2025 it issued $4.5 billion of new senior notes and used the proceeds to repay $2.0 billion of loans outstanding under the Term Loan Facility, the proceeds of which were used to fund an investment in Shields Health Solutions. The company said the remainder was used for general corporate purposes, including investments and repayment of indebtedness.

4. 04

   As of September 30, 2025, Cigna had $6.5 billion of undrawn committed capacity under its revolving credit agreement and $6.3 billion in cash and short-term investments, and its debt-to-capitalization ratio was 44.9%. During the 9 months ended 2025, the company repurchased 8.2 million shares for approximately $2.6 billion.

Key figures

Quarter ended September 30, 2025

Revenue

$69.7B

Operating income

$2.6B

Net income

$2.0B

EPS

$6.98

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.